emmanuelewumi:




It is an Indian owned medical diagnostic company with centres all over the country.



Made a profit after tax of over N2.6 billion and revenue of N27 billion in 2022

Sir I don't think they are diagnostic but more of medical production

emmanuelewumi:
By now we should know it is not good to buy a newly listed company or an Initial Public offer if you hope to hold for the long term, except you want to JIJO.


Transcorp IPO at N7.50 and later sold for less than N1 few years after


Dangote Sugar IPO at N18 and later sold for less N6 few years after.


Japaul IPO at N5 or thereabout

MTN IPO was N169

ebuka1997:


Sir I don't think they are diagnostic but more of medical production

What are they producing?


I use their lab at Oshodi for the medical tests of my mum and dad.


They have a very good eye clinic, that was where my late mum had her eye procedure

yMcy56:

There's a minimum to Cross Deals:
Must not be up to 100M on a single crossing, that's why you'll see something like 99,998,000 or thereabout in single crossing.....

The bid you're are seeing on top of the queue is not filled because most/all of the transactions you're seeing are cross deals......from one customer's account to another one (or to the broker's account).

Thanks a lot

Yoast:

Only 140,00 units traded so far yet no offer at moment. Why list on NGX when there's no supply

It's coming from the private section to public, the shareholders are still holding unto their shares I think.

There's a minimum requirement of free float (shares available to the public) which they must have met before listing.......in addition to other requirements.

With time, they'll have to release it for public trading on the floor......to accommodate more shareholders.

Same thing is still affecting VFD GROUP as well, it hasn't gone round......just cross dealings among themselves mostly for now.......except for the few shareholders that are bringing theirs out because it fell in price.

Think NGX needs to put some measures in place to ensure adequate quantities for trading as soon as any company is listed

unite4real:


MTN IPO was N169

Hope you know the terms of the offer, which helped to maintain the stock price. And besides MTN was on NGX for about 4 years before coming for an IPO.


Mecure should not sell for more than N1.20k, pending the time the market can place a premium on the stock

emmanuelewumi:



What are they producing?


I use their lab at Oshodi for the medical tests of my mum and dad.


They have a very good eye clinic, that was where my late mum had her eye procedure

The Company is principally in the business of manufacturing drugs (tablets, capsules and syrups) in Nigeria under two (2) categories namely Pharmaceuticals and Nutraceuticals.

The Pharmaceuticals segment comprises of forty-one (41) drugs such as Ebu 200 & 400 (ibuprofen tablets), Laclox (an ampiclox formulation), Lamox (an amoxicillin formulation) and Lampicin (an ampicillin formulation), used in treating different ailments.

The Nutraceuticals segment consist of 100 products including multivitamins and dietary supplements, the majority of which are imported from Youthberry (an American supplement manufacturing company).

While the Nutraceuticals segment is largely a trading line, the Company produces its pharmaceuticals drugs (predominantly branded generics) with support from its research and development team at its factory at Debo Industries Compound, Oshodi, Lagos State

https://www.google.com/amp/s/investogist.com/mecure-industries-plc-to-list-on-the-nigerian-exchange-by-introduction-at-n2-96-per-share/amp/

crownprince2017:
@mercy, is it a buying recommendation for mecure or what is your view on it?

Dont rush into it yet...
Not much info about it at the moment.

emmanuelewumi:



What are they producing?


I use their lab at Oshodi for the medical tests of my mum and dad.


They have a very good eye clinic, that was where my late mum had her eye procedure

more like third party production of prescription drugs, as GSK/other foreign pharma leave the country, maybe they and others can step in and purchase rights to produce and distribute from them.

ebuka1997:


more like third party production of prescription drugs, as GSK/other foreign pharma leave the country, maybe they and others can step in and purchase rights to produce and distribute from them.

It seems like they have around six business segments.
https://mecure.com.ng/index.html

Yoast:


The Company is principally in the business of manufacturing drugs (tablets, capsules and syrups) in Nigeria under two (2) categories namely Pharmaceuticals and Nutraceuticals.

The Pharmaceuticals segment comprises of forty-one (41) drugs such as Ebu 200 & 400 (ibuprofen tablets), Laclox (an ampiclox formulation), Lamox (an amoxicillin formulation) and Lampicin (an ampicillin formulation), used in treating different ailments.

The Nutraceuticals segment consist of 100 products including multivitamins and dietary supplements, the majority of which are imported from Youthberry (an American supplement manufacturing company).

While the Nutraceuticals segment is largely a trading line, the Company produces its pharmaceuticals drugs (predominantly branded generics) with support from its research and development team at its factory at Debo Industries Compound, Oshodi, Lagos State

https://www.google.com/amp/s/investogist.com/mecure-industries-plc-to-list-on-the-nigerian-exchange-by-introduction-at-n2-96-per-share/amp/

Then it is becoming a Medical Conglomerate. Production should be a new development, I have been patronizing their service for more than 10 years.

Just getting to know about pharmaceutical production.


With EPS of N1.30k in 2022, I don't understand why it was listed at almost N3.00.

Probably by 2023, we will start seeing the contribution of the production business in the financial performance of the company

I have not doubt about the growth of Mecure, people do come from other Western African countries, the management are also serious with business.


You can make money on the short run at the current price, but if you are one of those who want to invest for 5 years and above you need to wait, observe then strike

emmanuelewumi:




Hope you know the terms of the offer, which helped to maintain the stock price. And besides MTN was on NGX for about 4 years before coming for an IPO.


Mecure should not sell for more than N1.20k, pending the time the market can place a premium on the stock

I remember the terms then but i do not think the assertion holds mostly.

For example

BUA Foods got listed around N40 or so in January 2022

BUA Cement listed for N35 in January 2020

GEREGU is also an example

they have gone ahead to do better in a such a short time without looking back

essentialone:
CHAMS at 2.01
JAPAUL at 1.21

Is the Party over?

It was just a break in transmission that day. Party continues till 2.5 km junction.

unite4real:
I remember the terms then but i do not think the assertion holds mostly.
For example

BUA Foods got listed around N40 or so in January 2022
BUA Cement listed for N35 in January 2020
GEREGU is also an example

they have gone ahead to do better in a such a short time without looking back

VFD GROUP is another one I'm watching closely, that it may likely follow this pattern in the long run.

MECURE

The MECURE guys have come to move it up with +10% o.

21M bids don surface @3.25!!

Let's see if they planned to do some crossings here...

* Not any form of advice*

unite4real:


I remember the terms then but i do not think the assertion holds mostly.

For example

BUA Foods got listed around N40 or so in January 2022

BUA Cement listed for N35 in January 2020

GEREGU is also an example

they have gone ahead to do better in a such a short time without looking back

2 years is too short to make analysis for a long term investment, I look at minimum of 10 years.


Check what I wrote, I said those who want to make a long term investment should wait, observe and strike

yMcy56:

VFD GROUP is another one I'm watching closely, that it may likely follow this pattern in the long run.

their book value is currently around N165

Sanofi-Aventi Nigeria, a leading multinational pharmaceutical company, has disclosed its plans to discontinue direct operations in Nigeria in 2024.

This comes barely four months after GlaxoSmithKline (GSK) announced its exit from the Nigerian market, due to unfavourable economic forces after 51 years of operations in the country.

In a memo addressed to stakeholders in the healthcare industry on Tuesday titled “Sanofi adopts new business model in Nigeria”, signed by the Country Lead, Folake Odediran, and sighted by pharmanewsonline, it was stated that the global pharma company will be embarking on a transformative business model in Nigeria from February 2024.

The company explained that its new model will enable the commercialisation of Sanofi portfolio of medicines by a yet to be named 3rd party distributor.

"With effect from February 2024, our company will embark on an exciting transformation of its business model in Nigeria. In our new model, commercialization of Sanofi portfolio of medicines will be driven solely by a 3rd party soon to be named.

“The strategic move represents a significant milestone for our organisation and is driven by our commitment to continually improve access to our medicines and to better serve our patients and the Nigerian health system”.

She further disclosed that the multinational pharma giant is already in discussion with its employees, partners and major stakeholders to ensure a smooth and transparent transition process.

Odediran assured stakeholders on the commitment of the company to provide more value to patients, stating that that is the major reason for the adoption of the new model.

She said details of the new development will be provided in days ahead through media announcement.

“We have commenced with our employees, partners and key stakeholders, to ensure full transparency. In the coming days, we will make public announcement through the media. However, we recognise that our relationship with stakeholders is paramount and we wish to share this information with you in advance”, she revealed.

Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people they serve throughout the continuum of care.

From prevention to treatment, Sanofi’s scientific innovation into healthcare solutions, cuts across human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare.

who keeps buying PZ at 22 hmm

ebuka1997:
who keeps buying PZ at 22 hmm

after all, people still keep money in piggy bank.

unite4real:
their book value is currently around N165

If you see the list of stocks you mentioned, then you'll understand the pattern I talked about. Lol.

Did you check VFD's earning release and some investment explanations made as well?
They are of the opinion that things will be much brighter once the investments starts yielding as well.

WAPIC
Sighted @77k!
Have they increased the buyout price from 0.65k or what?

Let what happened in Ardova not repeat itself here o.

yMcy56:

If you see the list of stocks you mentioned, then you'll understand the pattern I talked about. Lol.

Did you check VFD's earning release and some investment explanations made as well?
They are of the opinion that things will be much brighter once the investments starts yielding as well.

That's my thought as well. You can see the number of outstanding shares sitting at around 190M.

VFD will shock many. those picking now should smile later

unite4real:
That's my thought as well. You can see the number of outstanding shares sitting at around 190M.

VFD will shock many

*Edited*

yMcy56:

VFD GROUP is another one I'm watching closely, that it may likely follow this pattern in the long run.

What are thr products or services

Streetinvestor2:
What are thr products or services

Different types.......ranging from Asset management, financial advisors, Oil & gas, Technology, Telecomms, power, real estates, healthcare and some other services .

yMcy56:

Different types.......ranging from Asset management, financial advisors, Oil & gas, Technology, Telecomms, power, real estates and some other services .

Please do you think Chams still has significant upside from current price?

yMcy56:

Outstanding shares is not even up to 8M!!
Hope I'm not mistaken o.
Where did you see the outstanding shares of 190M?

I saw this on print and online media when the news broke.

It's also on businesspost, investing, simplywallstreet, also on Nairametrics

https://leadership.ng/vfd-group-lists-190m-shares-on-ngx/#:~:text=The%20Nigerian%20Exchange%20Limited%2C%20has,Plc%20on%20its%20Main%20Board.

https://nairametrics.com/2023/10/14/vfd-group-seeks-approval-and-listing-63-34-million-ordinary-shares/ (when rights issue was sought)

Yoast:

Please do you think Chams still has significant upside from current price?

They are coming to the market to raise money for card centre subsidiary.
To me, they have already pushed the price.
Waiting for the official notice from the Group.
Might get to 2.50 to 3.00.

unite4real:
https://nairametrics.com/2023/10/14/vfd-group-seeks-approval-and-listing-63-34-million-ordinary-shares/ (when rights issue was sought)

You're right. My mistake.
Picked another figure instead...
So, It's not even up to 200M units.....190M (additional listed Rights Issue included)